Enhanced Cytotoxic Interaction Between 5-Fluorouracil and 4-Hydroperoxycyclophosphamide Against L1210 Murine Leukemic Cells: Applicability to Ex Vivo Purging

References

• Bacigalupo A, Van Lint M T, Frassoni F. Allogeneic bone marrow transplantation versus chemotherapy for childhood acute lymphoblastic leukemia in second remission. Bone Marrow Transplant 1986; 1: 75–80
   PubMed Web of Science ®Google Scholar
• Uderzo C, Valsecchi M G, Bacigalupo A. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 1995; 13: 352–358
   PubMed Web of Science ®Google Scholar
• Davies S M, Wagner J E, Shu X-O. Unrelated donor bone marrow transplantation for children with acute leukemia. J Clin Oncol 1997; 15: 557–565
   PubMed Web of Science ®Google Scholar
• Casper J, Camitta B, Truitt R. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 1995; 85: 2354–2363
   PubMed Web of Science ®Google Scholar
• Balduzzi A, Gooley T, Anasetti C. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247–3256
   PubMed Web of Science ®Google Scholar
• Kurtzberg J, Laughlin M, Graham M L. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335: 157–166
   PubMed Web of Science ®Google Scholar
• Laporte J-P, Gorin N-C, Rubinstein P. Cord-blood transplantation from an unrelated donor in an adult with chronic my-elogenous leukemia. N Engl J Med 1996; 335: 167–170
   PubMed Web of Science ®Google Scholar
• Borgmann A, Schmid H, Hartmann R. Autologous bone-marrow vansplants compared with chemotherapy for children with acute lymphoblastic lenkaemia in a second remission: a matched-pair analysis. Lancet 1995; 346: 873–876
   PubMed Web of Science ®Google Scholar
• Ramsay N, LeBien T, Nesbit M. Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission: results of bone marrow treated with monoclonal antibodies BA-1, BA-2, and BA-3 plus complement. Blood 1985; 66: 508–513
   PubMed Web of Science ®Google Scholar
• Aihara M, Aihara Y, Schmidt-Wolf G. A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy. Blood 1991; 77: 2079–2084
   PubMed Web of Science ®Google Scholar
• Anderson K C, Barut B A, Ritz J. Monoclonal antibody-purged autologous hone marrow transplantation therapy for multiple myeloma. Blood 1991; 77: 712–720
   PubMed Web of Science ®Google Scholar
• Martin-Henao G A, Ingles-Esteve J, Cancelas J A. Isolation of CD34+ hematopoietic progenitor cells in chronic myeloid leukemia by magnetic activated cell sorting (MACS). Bone Marrow Transplant 1996; 18: 603–609
   PubMed Web of Science ®Google Scholar
• Willems P, Croockewit A, Raymakers R. CD34 selections from myeloma peripheral blood cell autografts contain residual tumor cells due to impurity, not to CD34+ myeloma cells. Br J Haematol 1996; 93: 613–622
   PubMed Web of Science ®Google Scholar
• Mulroney C M, Gluck S, Ho A D. The use of photodynamic therapy in bone marrow purging. Semin Oncol 1994; 21: 24–27
   PubMed Web of Science ®Google Scholar
• Sieber F, Sieber-Blum. Dye-mediated photosensitization of mu-rine neuroblastoma cells. Cancer Res 1986; 46: 2072–2076
   PubMed Web of Science ®Google Scholar
• Muench M O, Guy Z, Moore M AS. Ex vivo differentiation therapy as a method of leukemic cell purging in murine bone marrow expansion cultures. Cancer Res 1992; 52: 6576–6582
   PubMed Web of Science ®Google Scholar
• Yeager A M, Kaizer H, Santos G W. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia. using ex vivo marrow treatment with 4-hydroperoxycyclo-phosphamide. N Engl J Med 1986; 315: 141–147
   PubMed Web of Science ®Google Scholar
• Sharkis S J, Oantos GW, Colvic M. Flimination of acute myelogenous leukemic cells from marrow an tumor suspensions in the rat with4-hydroperoxycyclophospllamide. Blood 1980; 55: 521–523
   PubMed Web of Science ®Google Scholar
• Douay L, Hu C, Giarratana M C. Amifostine improves the antileukemic therapeutic index of mafosmamide: implications for bone marrow purging. Blood 1995; 86: 2849–2855
   PubMed Web of Science ®Google Scholar
• Laporte JPh, Douay L, Lopez M. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. Blood 1994; 84: 3810–3818
   PubMed Web of Science ®Google Scholar
• Bettan-Renaud L, De Vathaire F, Benard J. Potential therapeutic role of cisplatinum in autologous bone marrow transplantation in vitro eradication of neuroblastoma cells from bone marrow. Br J Cancer 1989; 60: 529–532
   PubMed Web of Science ®Google Scholar
• Sugarbaker P H, Gianola F J, Barofsky I. 5-Fluorouracil chemotherapy and pelvic radiation in the treatment of large bowel cancer. Cancer 1986; 58: 826–831
   PubMed Web of Science ®Google Scholar
• Vokes E E, Weichselbaum R R. Concomitant chemoradiotherapy: rationale and clinical experiments in patients with solid tumors. J Clin Oncol 1990; 8: 911–934
   PubMed Web of Science ®Google Scholar
• Miller E M, Kinsella T J. Radiosensitization by fluorodeoxyuridine: effects of thymidylate synthase inhibition and cell synchronization. Cancer Res 1992; 52: 1687–1694
   PubMed Web of Science ®Google Scholar
• Jazwiec B, Mahon F X, Pigneux A. 5-Fluorouracil-resistant CD34+ cell population from peripheral blood of CML patients contains BCR-ABL-negative progenitor cells. Exp Hematol 1995; 23: 1509–1514
   PubMed Web of Science ®Google Scholar
• Stewart F M, Temeles D, Lowry P. Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation. Blood 1993; 81: 2283–2289
   PubMed Web of Science ®Google Scholar
• Kakito H, Ohkubo T, Kagawa Y. Effect of 5-fluorouracil and a combination of tegafur and uracil (UFT) on nucleotide metabolism in L1210 ascites tumor. Cancer Invest 1993; 11: 530–533
   PubMed Web of Science ®Google Scholar
• Kagawa Y, Ohkubo T, Higashigawa M. Effect of UFT (mixed compound of tegafur and uracil) on cell kinetics and inhibition of thymidylate synthase in L1210 ascites tumor. Cancer Invest 1995; 13: 470–474
   PubMed Web of Science ®Google Scholar
• Gianni A M, Bregni M, Siena S. Recombinant human granu-locyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclo-phosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 768–778
   PubMed Web of Science ®Google Scholar
• Mabel J A, Merker P C, Sturgeon M L. Combination chemotherapy against B16 melanoma: bleomycin/vincristine. bleomycinlcis-diamminedichloroplatinum, 5-fluorouracil/BCNU and 5-fluorouracil/methyl-CCNU. Cancer 1978; 42: 1711–1719
   PubMed Web of Science ®Google Scholar
• Pieters R, Loonen A H, Huismans D R. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327–2336
   PubMed Web of Science ®Google Scholar
• Chou T-C, Talalay P. Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. New Avenues in Developmental Cancer Chemotherapy, KR Harrap, TA Connors. Academic Press, Orlando 1987; 37–64
   Google Scholar
• Higashigawa M, Cao D-C, Matsui K. Combined oral administration of etoposide and arabinofuranosylcytosine-5′-steary-phosphate enhances the antitumor effect against P388 ascites tumors. Cancer Chemother Pharmacol 1994; 33: 281–285
   PubMed Web of Science ®Google Scholar
• Ohkubo T, Higashigawa M, Kawasaki H. Sequence-dependent antitumor effect of VP-16 and 1–β-D-arabinofuranosylcyto-sine in L1210 ascites tumor. Eur J Cancer Clin Oncol 1988; 24: 1823–1828
   PubMedGoogle Scholar
• Hug V, Thames H, Hortobagyi G. Chemosen Titivities of human clonogenic breast tumor cells. Eur J Cancer Clin Oncol 1986; 22: 921–981
   PubMedGoogle Scholar
• Erickson L C, Bradley M O, Ducore J M. DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas. Proc Natl Acad Sci USA 1990; 77: 467–471
   Google Scholar
• Crathome A R, Roberts J J. Mechanism of the cytotoxic action of alkylating agents in mammalian cells and evidence for the removal of alkylated groups from deoxyribonucleic acid. Nature 1966; 211: 150–153
   PubMed Web of Science ®Google Scholar
• Tanaka R, Katayama N, Ohishi K. Accelerated cell-cycling of hematopoietic progenitor cells by growth factors. Blood 1995; 86: 73–79
   PubMed Web of Science ®Google Scholar